{"id":94888,"topic":"ai","source":"生物通","title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","url_hash":"d175196b6224206ca8a028bbeed7e236a086a4b0","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMibkFVX3lxTE95RWQtbVhvNHQtWHN0S0tyVzBYbHluOWFheXo4Q2l2ZWhPYVBoaThQZXc1eFllRXRoQkw0Q1lwWTg4S29zb2hZYV9od081NTFMSVMwUl9XWkt3X3NxakxaQ0d3TUY2YzVpOGNic1NR?oc=5\" target=\"_blank\">人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物通</font>","content":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","image_url":null,"lang":"zh","published_at":"2026-10-03T01:05:14+00:00","fetched_at":"2026-10-03T01:15:06+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 5518 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":5518,"summary_length":5518,"usable_text_length":5518,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":5518,"summary_length":5518}},"news_item":{"id":94888,"canonical_url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","source_url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","source_name":"生物通","author":null,"published_at":"2026-10-03T01:05:14+00:00","locale":"zh","topic":"ai","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMibkFVX3lxTE95RWQtbVhvNHQtWHN0S0tyVzBYbHluOWFheXo4Q2l2ZWhPYVBoaThQZXc1eFllRXRoQkw0Q1lwWTg4S29zb2hZYV9od081NTFMSVMwUl9XWkt3X3NxakxaQ0d3TUY2YzVpOGNic1NR?oc=5\" target=\"_blank\">人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">生物通</font>","full_text":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","excerpt":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 5518 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 5518 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":5518,"summary_length":5518,"usable_text_length":5518,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":5518,"summary_length":5518}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","summary":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","source":"生物通","date":"2026-10-03T01:05:14+00:00","content":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 5518 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 5518 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":5518,"summary_length":5518,"usable_text_length":5518,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":5518,"summary_length":5518}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/94888","export_markdown":"/api/items/94888/export?format=markdown","export_json":"/api/items/94888/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm"},"formats":{"full":{"id":94888,"title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","source":"生物通","author":null,"published_at":"2026-10-03T01:05:14+00:00","locale":"zh","topic":"ai","tags":[],"excerpt":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","full_text":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 5518 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 5518 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":5518,"summary_length":5518,"usable_text_length":5518,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":5518,"summary_length":5518}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 5518 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":5518,"summary_length":5518,"usable_text_length":5518,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":5518,"summary_length":5518}},"actions":{"read":"/item/94888","export_markdown":"/api/items/94888/export?format=markdown","export_json":"/api/items/94888/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm"}},"digest":{"id":94888,"title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","source":"生物通","topic":"ai","published_at":"2026-10-03T01:05:14+00:00","excerpt":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation ±à¼ÍƼö£º ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 5518 characters.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","subtitle":"生物通 · 2026-10-03","summary":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation ±à¼ÍƼö£º ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s…","badges":["quality:high"],"links":{"read":"/item/94888","original":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","diagnose":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm"},"quality_warning":null},"export":{"title":"人工智能在阿尔茨海默病中：从临床生物标志物智能到治疗创新 - 生物通","url":"https://www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","summary":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","source":"生物通","date":"2026-10-03T01:05:14+00:00","content":"¡¶Acta Pharmaceutica Sinica B¡·£ºArtificial intelligence in Alzheimer¡¯s disease: From clinical biomarker intelligence to therapeutic innovation\n        \n        \t\n            \t±à¼ÍƼö£º\n                \n                ¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µä\n                \n\t\t\t\t\n             \n            \n\t\t\t\n         \n        \n        ¡¡¡¡\n°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈ«Çò³Õ´ôµÄÊ×Òª²¡Òò£¬Ò²ÊÇÈ«Çò·¢²¡ÂÊ¡¢ËÀÍöÂʺÍÒ½ÁÆÖ§³öÔö³¤µÄÖØÒªÇý¶¯ÒòËØ¡£¾¡¹Ü¾¹ýÊýÊ®ÄêµÄÉîÈëÑо¿£¬ÔÚÔçÆÚ¼ì²â¡¢·çÏÕ·Ö²ãºÍÓÐЧÖÎÁÆ·½Ãæ½øÕ¹ÓÐÏÞ£¬Õâ·´Ó³Á˸ü²²¡µÄÉúÎïѧ¸´ÔÓÐÔ¡¢ÒìÖÊÐԺͳ¤ÁÙ´²Ç°½ø³Ì¡£¾µäÉúÎï±êÖ¾Î¡ª×îÏÔÖøµÄÊǵí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ºÍtau¡ª¡ª½öÄܲ¶×½ADÁ¬ÐøÆ×Öй۲쵽µÄ·Ö×ÓºÍÁÙ´²±äÒìµÄһС²¿·Ö£¬ÏÞÖÆÁËÁÙ´²¾ö²ßºÍÖÎÁÆ¿ª·¢¡£È˹¤ÖÇÄÜ£¨artificial intelligence£¬AI£©µÄ×îнøÕ¹ÕýÔÚÖØËÜADÉúÎï±êÖ¾ÎïÑо¿£¬Ê¹¿ç·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪºÍÁÙ´²ÁìÓòµÄ¸ßά¶àģ̬Êý¾ÝµÄÕûºÏ¡¢½¨Ä£ºÍ½âÊͳÉΪ¿ÉÄÜ¡£ÖØÒªµÄÊÇ£¬AI½«ÉúÎï±êÖ¾Îï´Ó¼²²¡´æÔڵľ²Ì¬Ö¸±ê£¬ÖØй¹½¨Îª¿É¸æÖª¼ì²â¡¢ÉúÎïѧ·ÖÆںͼ²²¡¹ì¼£Ô¤²âµÄ¶¯Ì¬Ðźš£ÕâЩ½øÕ¹½ø¶øͨ¹ýÉúÎï±êÖ¾ÎïÒýµ¼µÄ°ÐµãÓÅÏȼ¶ÅÅÐò¡¢Ò©ÎïÖض¨Î»£¨drug repurposing£©ºÍ´ÓÍ··Ö×ÓÉè¼Æ£¨de novo molecular design£©¿ªÊ¼±ä¸ïÖÎÁÆ·¢ÏÖ¡£ÔÚ±¾×ÛÊöÖУ¬Ñо¿ÈËÔ±¶Ô¿çÍêÕûת»¯Æ×µÄAIÇý¶¯ADÉúÎï±êÖ¾Îï·¢ÏÖ·½·¨½øÐÐÁËÅúÅÐÐÔ×ۺϣ¬Í»³ö¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§¾ÖÏÞ£¬ÒÔ¼°ÁÙ´²ºÍÖÆҩʵʩµÄ¹Ø¼üÒªÇ󣬽«AI¶¨Î»ÎªAD¾«×¼Ò½Ñ§µÄºËÐÄÒýÇæ¡£\nÑо¿±³¾°·½Ã棬°¢¶û´Äº£Ä¬²¡£¨Alzheimer¡¯s disease£¬AD£©ÊÇÈÕÒæÑÏÖصÄÈ«Çò¹«¹²ÎÀÉúΣ»ú£¬ÁÙ´²±íÏÖΪÈÏÖª½øÐÐÐÔϽµ£¬´ÓÇé¾°¼ÇÒäȱÏÝÖð½¥ÀÛ¼°ÓïÑÔ¡¢ÊÓ¿Õ¼äºÍÖ´Ðй¦ÄÜ¡£Ä¿Ç°È«ÇòADÁ¬ÐøÆ×ÖаüÀ¨Ô¼3200Íò³Õ´ô»¼Õß¡¢6900ÍòÇ°ÇýÆÚADºÍ3.15ÒÚÁÙ´²Ç°AD£¬ºÏ¼Æ³¬¹ý4ÒÚÈ˾ßÓÐÉúÎïѧ»òÁÙ´²ADÌØÕ÷¡£¾¡¹ÜADNIµÈ¼Æ»®²úÉúÁË´óÁ¿×ÝÏòÊý¾Ý£¬µ«´«Í³Í³¼ÆºÍ¼ÙÉèÇý¶¯·½·¨ÄÑÒÔ´¦Àí¸ßά¡¢ÒìÖʺÍʱÐòÊý¾Ý¡£¾µäÉúÎï±êÖ¾ÎïÈçµí·ÛÑùµ°°×-¦Â£¨amyloid-¦Â£¬A¦Â£©ÓëtauÖ»Äܲ¶×½ÓÐÏÞ±äÒ죬ÔçÆÚ¼ì²â¡¢¹ì¼£Ô¤²âºÍÖÎÁƿɲÙ×÷ÐÔÖ®¼ä´æÔÚÃ÷ÏԺ蹵£¬Òò´ËؽÐè¿ÉÕûºÏ¶àÔ´Êý¾Ý²¢·þÎñÁÙ´²ÓëÖÆÒ©¾ö²ßµÄпò¼Ü¡£\nÑо¿ÈËÔ±¿ªÕ¹µÄÊÇһƪ·¢±íÔÚ¡¶Acta Pharmaceutica Sinica B¡·µÄ×ÛÊöÑо¿£¬¶ø·ÇÔʼʵÑé¡£Ñо¿ÈËÔ±°´×ª»¯Âß¼×é֯ȫÎÄ£ºÏÈÌÖÂÛAIÈçºÎ°ÑÄÔ¼¹Òº£¨cerebrospinal fluid£¬CSF£©¡¢ÑªÒº¡¢ÊÓÍøĤºÍÐÐΪµÈ²âÁ¿×ª»¯Îª¼ì²â¡¢ÉúÎïѧ·ÖÆÚÓë¹ì¼£Ô¤²âÐźţ»ÔÙÌÖÂÛÕâЩÐźÅÈçºÎÖ§³Å»¼ÕßÑ¡Ôñ¡¢ÊÔÑ鸻¼¯ºÍÖÎÁƾö²ß£»×îºóÌÖÂÛÉúÎï±êÖ¾ÎïÖÇÄÜÈçºÎ½øÈë°ÐµãÓÅÏȼ¶¡¢Ò©ÎïÖض¨Î»ºÍ´ÓÍ··Ö×ÓÉè¼Æ¡£½áÂÛÉÏ£¬AIµÄ¼ÛÖµ²»ÔÚÓÚÌæ´ú¼ÈÓÐÉúÎï±êÖ¾Î¶øÔÚÓڰѾ²Ì¬Ö¸±êתΪ¶¯Ì¬¼²²¡ÖÇÄÜ£¬Ê¹Õï¶Ï¡¢Ô¤ºóºÍÖÎÁÆAIÑо¿ÄÉÈëͳһ¿ò¼Ü£ºµ±ÉúÎï±êÖ¾ÎïÄÜ°ïÖú·ÖÆÚ¡¢Ô¤²â¹ì¼£¡¢Ñ¡Ôñ»¼Õß»òʹÖÎÁƼÙ˵¸üÒ×¼ìÑéʱ£¬²Å¾ßÓÐÁÙ´²ÓÃ;¡£¸Ã×ÛÊöµÄÖØÒªÒâÒåÔÚÓÚΪAD¾«×¼Ò½Ñ§Ìṩ¸ÅÄî¿ò¼Ü¡¢·½·¨Ñ§±ß½çºÍת»¯ÊµÊ©ÒªÇó¡£\n¹Ø¼ü¼¼Êõ·½·¨ÉÏ£¬Ñо¿ÈËԱʹÓÃADNI¡¢BioFINDER¡¢Knight ADRC¡¢UK Biobank¡¢ARICµÈ¶ÓÁÐÓë¶àÖÐÐÄÊý¾Ý£»²ÉÓóͷ£»Ø¹é£¨LASSO¡¢µ¯ÐÔÍøÂ磩¡¢Éú´æÄ£ÐÍ£¨Cox£©¡¢Ê÷¼¯³É£¨Ëæ»úÉÁÖ¡¢ÌݶÈÌáÉý¡¢XGBoost¡¢LightGBM£©¡¢Éî¶Èѧϰ£¨CNN¡¢RNN¡¢Transformer¡¢Í¼Éñ¾ÍøÂ磩¡¢¿É½âÊÍ·½·¨£¨SHAP£©ÒÔ¼°Î޼ල·½·¨£¨¸ß˹»ìºÏÄ£ÐÍ¡¢PCA¡¢SCORPIUS£©½øÐÐÌØÕ÷Ñ¡Ôñ¡¢·ÖÆÚ¡¢Ô¤²âºÍ½âÊÍ£»²¢Í¨¹ýÍⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢µç×Ó½¡¿µ¼Ç¼£¨electronic health record£¬EHR£©ºÍÊÔÑéÊý¾ÝÆÀ¹Àת»¯Ö¤¾Ý¡£\nÑо¿½á¹û²¿·Ö£¬2. AI¸³ÄܵÄADÁ¬ÐøÆ×ÁÙ´²ÉúÎï±êÖ¾ÎïÖÇÄÜÖУ¬Ñо¿ÈËÔ±Ö¸³öÕï¶ÏÓëÔ¤²â±ß½ç¶àΪ²Ù×÷ÐÔ¶ø·ÇÉúÎïѧÐÔ£¬AI¿ÉÕûºÏ¶àÔ´Êý¾Ý¡¢´¦ÀíȱʧÓëɾʧ¡¢Çø·ÖÄêÁäÏà¹Ø¸Ä±äÓë¼²²¡¹ì¼£¡£2.1 ÇÖÈëÓë΢´´ÉúÎï±êÖ¾Î¸ßÌØÒìÐÔ¼²²¡ÖÇÄÜÏ£¬2.1.1 ÄÔ¼¹ÒºÉúÎï±êÖ¾ÎïÏÔʾ£¬CSFÖÐA¦Â42×îÔçÆ«À룬ԼÕï¶ÏÇ°18Ä꣬ËæºóA¦Â42/A¦Â40¡¢p-tau181¡¢t-tauÒÀ´Î±ä»¯£»LASSOÊ®µ°°×Ãæ°å¶ÔÉúÎï±êÖ¾ÎïÑôÐÔʶ±ðAUC>0.98£¬Ê÷¼¯³ÉÔ¤²âMCIÖÁAD 3Äêת»¯Ô¼84%׼ȷ£¬µ¯ÐÔÍøÂç¿ÉÔ¤²âMoCAÄêϽµ£¨r¡Ö0.62£©£¬MTBR-tau243ÌáÉýtau²¡ÀíÌØÒìÐÔ£¬XGBoostÖÊÆ×Ãæ°åAUC¡Ö0.91£¬¸ß˹»ìºÏÄ£ÐÍ»¹¿É¸ø³ö¿çÖÐÐÄÎȶ¨µÄÊý¾ÝÇý¶¯Çе㡣2.1.2 ѪҺÉúÎï±êÖ¾ÎïÏÔʾ£¬Ñª½¬µ°°××é½áºÏµ¯ÐÔÍøÂç/Cox¿ÉÔ¤²â5ÖÁ20Äê³Õ´ô·çÏÕ£¬LightGBM+CoxÄ£ÐÍÖÐGFAP¡¢NEFL¡¢GDF15¡¢LTBP2µÈ¿ÉÌáÇ°10ÖÁ15ÄêÔ¤²âAD£¨AUC=0.872£©£»cf-mRNA¡¢»ùÒò±í´ïÃæ°åÕï¶ÏAUCÔ¼0.83ÖÁ0.86£»ATR-FTIRÓëSERSµÈ¹âÆ×AI·½·¨¾ßÔçɸDZÁ¦µ«ÐèÍⲿÑéÖ¤¡£2.2 ·ÇÇÖÈëÉúÎï±êÖ¾Î¿É¹æÄ£»¯µÄÊײ㼲²¡ÖÇÄÜÖУ¬2.2.1 ÊÓÍøĤ³ÉÏñÏÔʾ£¬OCTÖÐmRNFLÿ½µµÍ5 ¦Ìm·çÏÕÔ¼Ôö15%£¬×îµÍÎå·Öλ·çÏÕ¸ßÔ¼60%£»RetiPhenoAge¡¢EfficientNet-b2¡¢OCTAͼģÐÍEye-ADÔÚɸ²éºÍ΢Ѫ¹Ü·ÖÎöÖбíÏÖÇ¿£¬µ«ÊÜÇà¹âÑÛ¡¢ÌÇÄò²¡ÊÓÍøĤ²¡±äºÍÉ豸ÒìÖÊÓ°Ï죬ÒË×÷·Ö²ãǰɸ²é¡£2.2.2 ÐÐΪÉúÎï±êÖ¾ÎïÏÔʾ£¬ÓïÒô¡¢Îı¾¡¢Ã沿¡¢ÑÛ¶¯¾NLP¡¢SVM¡¢LSTM¡¢×Ô±àÂëÆ÷½¨Ä£¿É»ñ½Ï¸ß׼ȷÂÊ£¬µ«ÊÜ·½ÑÔ¡¢½ÌÓý¡¢¹âÕÕ¡¢ÈÎÎñÒÀ´ÓÓ°Ï죬СÑù±¾½á¹û¶àΪ¸ÅÄîÑéÖ¤£¬ÊʺÏ×ö·ÖÕï¶ø·ÇÈ·Õï¡£2.3 ¶àģ̬ģÐÍÓëÁÙ´²Ð§ÓÃÏÔʾ£¬Transformer¡¢¶à×éѧ¡¢EHRÄ£ÐÍ¿ÉÔ¤²âA¦Â/tau״̬Óë·¢²¡·çÏÕ£¬Á¬Ðø¸ÅÂÊÓÅÓÚAT[N]¶þ·Ö£»AIÔ¤ºóбäÁ¿¿ÉÓÅ»¯lecanemabÊÔÑéЧÄÜ¡¢¼õÉÙÑù±¾Á¿£¬¶àģ̬¼ÛÖµÔÚ¸üºÃ¾ö²ß¶ø·Ç½ö¸ü¸ßAUC¡£\n- 3.AIÇý¶¯µÄADÒ©Îï·¢ÏÖÖУ¬Ñо¿ÈËÔ±×ܽáÈý·½Ïò£º°Ðµãʶ±ðÓëÓÅÏȼ¶ÓÃGWAS¡¢PPI¡¢¶à×éѧºÍÍøÂ籴Ҷ˹¡¢GNN£¬Ê¶±ðAD·çÏÕ»ùÒòÓë¿É³ÉÒ©°Ðµã£¬²¢ÓÃEHRÑéÖ¤²¼Âå·Ò¡¢·Çŵ±´ÌØÀࡢͷæßÇúËɵÈÖض¨Î»ÏßË÷£»Ò©ÎïÖض¨Î»ÓÃͼÓëÒ©ÀíÄ£ÐÍÔÚ»úÖÆ¡¢°²È«ºÍѪÄÔÆÁÕÏÔ¼ÊøÏÂÅÅÐòÀÏÒ©»ò×éºÏ£»´ÓÍ·Éè¼ÆÓÃÉú³ÉÄ£ÐÍÔÚ»¯Ñ§»òëÄ¿Õ¼äÓÅ»¯ºòÑ¡·Ö×Ó¡£½áÂÛÉÏ£¬AI°Ñ¶à×éѧ¡¢ÍøÂçÓ뻯ѧÊý¾ÝÄÉÈë¡°¼ÆË㡪ʵÑ顱ѻ·£¬Ê¹°Ðµã·¢ÏÖ¡¢ÀÏÒ©ÐÂÓúͷÖ×ÓÉú³É¸üϵͳ¡£ \nÌÖÂÛÓë½áÂÛ·Ò룺ADµÄAIÉúÎï±êÖ¾ÎïÑо¿Õý´Óµ¥Ä£Ì¬·ÖÀà×ßÏò¶àģ̬¡¢¿É½âÊͺÍ×ÝÏò¼²²¡ÖÇÄÜ¡£Ñо¿ÈËԱǿµ÷£¬¸ßAUC²»µÈÓÚÁÙ´²¿ÉÓ㻽öÓÐÄÚ²¿½»²æÑéÖ¤¡¢»Ø¹Ë²¡Àý¶ÔÕÕ»òµ¥ÖÐÐÄÊý¾ÝµÄÑо¿Êô̽Ë÷ÐÔ£¬¶ÀÁ¢Íⲿ¶ÓÁС¢×ÝÏòËæ·Ã¡¢ÕæʵÊÀ½çEHR¡¢ÊÔÑéÊý¾ÝºÍÇ°Õ°¹¤×÷Á÷²âÊÔ²ÅÌṩ¸üǿת»¯Ö¤¾Ý¡£Î´À´Ó¦Íƶ¯¼ì²âƽ̨±ê×¼»¯¡¢ÈËȺ´ú±íÐÔ¡¢Èõ¼à¶½/×ԼලѵÁ·¡¢¿É½âÊ;ö²ßϵͳºÍÇ°Õ°ÑéÖ¤¡£ÉúÎï±êÖ¾ÎïÖÇÄܵijÉÊ콫ʹ·ÇÇÖÈ빤¾ß¸ºÔðɸ²é·ÖÕѪҺģÐ͸ºÔð¼à²âÓë·Ö²ã£¬CSF/PET¸ºÔð²¡ÀíÈ·ÈÏ£¬½ø¶øÖ§³Å¸üÔçÈë×é¡¢ÊÔÑ鸻¼¯¡¢°ÐµãÓÅÏȼ¶ºÍ¾«×¼ÖÎÁÆ¡£AI²»Ó¦±»Àí½âΪÌæ´úÒ½Éú»ò´«Í³±êÖ¾Î¶øÊÇ°Ñ·Ö×Ó¡¢Ó°Ïñ¡¢ÐÐΪÓëÁÙ´²Êý¾Ýת»¯Îª¿ÉÐж¯¼²²¡ÖÇÄܵĺËÐÄ»ù´¡ÉèÊ©£¬×îÖÕÍƶ¯AD´Ó¾ÑéÐÔ³Õ´ô¹ÜÀí×ßÏòÉúÎïѧ¼Ò¶¨Òå¡¢Êý¾ÝÇý¶¯ºÍ°ÐÏò¿É¼°µÄ¾«×¼Ò½Ñ§¡£","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.ebiotrade.com/newsf/2026-10/20261003090030267.htm","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 5518 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 5518 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":5518,"summary_length":5518,"usable_text_length":5518,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":5518,"summary_length":5518}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}